Ocean Park Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Ocean Park Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-43,823	Closed	-$7.4M	–	78
2025 Q4	$7.4M	Buy	+43,823	New	+$7.12M	0.35%	40
2023 Q1	–	Sell	-82,800	Closed	-$10.9M	–	20
2022 Q4	$10.9M	Buy	+82,800	New	+$10.7M	0.69%	12

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ocean Park Asset Management's IBB Position: Q1 2026 in Review

Ocean Park Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 43,823 shares — an estimated $7.4M sold.

Ocean Park Asset Management first reported a position in IBB in Q4 2022 and held it in 2 quarters. The position peaked at $10.9M in Q4 2022. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Ocean Park Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
Ocean Park Asset Management sold 43,823 iShares Biotechnology ETF shares in Q1 2026, an estimated $7.4M.
Ocean Park Asset Management first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 2 quarters.
Ocean Park Asset Management's iShares Biotechnology ETF position peaked at $10.9M in Q4 2022.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Ocean Park Asset Management's 13F filing for Q1 2026, filed 15 Apr 2026.